Pfizer – IBM – Collaborate – Internet of Things – 2017

IN Hackable-Humans
  • Updated:1 year ago
  • Reading Time:10Minutes
  • Post Words:2464Words
Print Friendly, PDF & Email

First Published: 24 October, 2022 | Last Updated: 25 April 2023

Has Moderna has joined the party? (Update 25 April 2023) On April 20, 2023, CNBC published an article “Moderna teams up with IBM to put A.I., quantum computing to work on mRNA technology used in vaccines” (01)

  • Moderna and IBM are teaming up to use generative artificial intelligence and quantum computing to advance mRNA technology, the development at the core of the company’s Covid vaccine. 
  • The companies said they signed an agreement that would allow Moderna to access IBM’s quantum computing systems and generative AI model.
  • The agreement comes as Moderna navigates its post-pandemic boom driven by its mRNA Covid vaccine. 

Confirmed on Moderna’s Investor News – Download PDF (02)

Although no mention of the Internet of Things, Internet of Bodies, or Internet of Humans on the article or the investor newsletter, Moderna rubbing shoulders with IBM doesn’t pass the smell test, particularly because of all the things we know about Moderna already (made in “hours”, no previous product to market, funded by Fauci/Gates/USgov, the booster-mice, the CEO’s connection to Wuhan lab, the patented DNA strands in the “virus”, the lethal dose-sizing, the partnership with DARPA, the connection to US Military, the “master patent” that shows quantumdots and other shenanigans in the jabs, the vial pictures looking very “technological in nature”, and on and on and on, there’s no reason to trust these crooks)… (browse tag “moderna” so I don’t have to individually cite all the refs if any of this is new to you), but we don’t want Moderna teaming up with IBM for anything, particularly anything that gives them any kind of advantage to push more bioweapons, but also with IBM & Pfizer’s “Internet of Things” collaboration – it raises the red flags even higher.

Pfizer & IBM became partners in 2017 “to transform healthcare into the 21st century” by attaching sensors to the body and environment to the “Internet of Things”.

Rumble | Telegram

Source: Official Pfizer Video from their #PfizerPartnerships Facebook Page

We are working with IBM on an effort to transform Parkinson’s care. This collaboration is designed to harness the Internet of Things, monitoring the patient’s health and quality of life in real-time.

~ Pfizer, March 21, 2017

Imagine a world in which you could measure by watching a person act or move or move through space, or just be themselves as they’re going through their daily life. Imagine if you could capture that information and say “Ok, this tells me the state of health of this patient”. ~ Peter Bergethon, MD, VP of Quantitative Medicine Neuroscience & Pain Research Unit, Pfizer

… and to do so, you really have to monitor the symptoms that the individual is having pretty much on a continuous basis. Not just episodically, bringing them into the clinic and measuring it once. The problem in the theory of chronic neurological diseases like Parkinson’s, is that the symptoms of the patient experiences, vary minute by minute”. ~ Ajay Royyuru, PhD, Director, Healthcare & Life Sciences, IBM Research

What we’ll do is we’ll basically put a sensor or a series of sensors on the patient or in their environment. The sensors will measure how they move, what their body temperature is, or whether or not they open the refrigerator door. So they’re going to give us information about how the patient is doing, and how they’re interacting with the environment. ~ Pfizer

So, the solution that we’re working on, with Pfizer, is going to take a lot of data continuously from sensors, measurements on the person, measurements in the environment, and actually then, deploy a large body of machine learning algorithms that they have developed and apply here to be able to say which of these symptoms correspond in what manner to what kind of accepted clinical end-points.

Insights from these data points could help the doctor understand and qualify the magnitude of symptoms that the patients is having and in turn, use that information to help tailor the treatment, the dosage, and all other things that are being done to address the symptoms of the patient. ~ IBM

It’s time for medicine to move into the 21st century, and this is the opportunity literally to change the world. The idea that you take a broken body, and you restore it, it just doesn’t get any better than that. ~ Pfizer

Worse, is this particular announcement on the IBM website – April 14, 2022

The International Science Reserve Announces Executive Board and Unveils its First Crisis Activation on Wildfire Prevention and Management

The ISR network unites 1000+ scientists from around the world in a collaborative effort to solve some of the most pressing global challenges with support from New York Academy of Sciences, Google, IBM, Pfizer, UL, Rockfeller Institute, and Grossman’s Department of Population Health

The New York Academy of Sciences (NYAS) and its founding members — including Google, IBM, Pfizer, and UL — today announced the official activation of the International Science Reserve (ISR). Recognizing that our world’s scientific capacity exists across borders, institutions, and sectors, the ISR brings together global scientists across government, academia, and industries to collaborate across geographies and sectors to prepare for and help mitigate potential global crises – from future pandemics to the consequences of climate change. 

As part of its ongoing mission, the ISR will facilitate access to specialized scientific and technical resources around the world; conduct scenario planning readiness exercises to increase preparation and anticipation of global impacts, and convene scientists from a wide range of countries to build institutional memory in crisis management and response. This initiative builds on the success of the IBM-led High Performance Computing Consortium (HPCC), which was established in March 2020 in response to the COVID-19 pandemic

At the helm of the organization is a newly created Executive Board with recognized science leaders from multiple sectors: 

  • Nicholas Dirks, PhD, President and Chief Executive Officer, New York Academy of Sciences and Co-Chair, ISR Executive Board
  • Darío Gil, PhD, Senior Vice President and Director, IBM Research and Co-Chair, ISR Executive Board
  • Aida Habtezion, MD, MSc, FRCPC, AGAF, Senior Vice President, Chief Medical Officer, and Head of Worldwide Medical & Safety, Pfizer Inc.
  • Philip Nelson, Research Lead, Google
  • Robert Slone, PhD, Senior Vice President and Chief Scientist, UL (Former Honeywell)
  • Rick Bright, PhD, CEO, Pandemic Prevention Institute and Senior Vice President, The Rockefeller Foundation (Former BARDA director)
  • Lorna Thorpe, PhD, Professor and Director of the Division of Epidemiology, NYU Grossman School of Medicine in the Department of Population Health Grossman School of Medicine, Department of Population Health

The Board will conduct detailed research and analysis to advise on the nature and scope of the crisis area that the ISR will address. When a crisis of transnational scale and sufficient urgency occurs, the Executive Board mobilizes the ISR. Additionally, Mila Rosenthal, PhD, was recently announced as the Executive Director for the ISR. 

“Science in the time of crisis is rapid, requiring quick decisions, on the basis of limited information,” says President and CEO of NYAS, Nicholas Dirks. “Scientists should and indeed must play a critical role in the development of effective strategies for responding to crises — from evaluating the multiple effects of different kinds of crises to providing possible solutions and directions for mitigation, immediate and short term as well as long term. We are creating a collaborative entity in the International Science Reserve that will help us to anticipate and prepare for what might be needed to respond to the next global crisis in the best possible way.”

“The world needs the International Science Reserve,” says IBM Senior Vice President and Director of IBM Research, Darío Gil. “Great crises have often been catalysts for institutional innovation in science and technology. The National Science Foundation and the U.S. National Laboratories were created after WWII. NASA and DARPA emerged during the Cold War. Our current crises demand that we innovate again, and this time, an international network of scientists spanning the private sector, academia, non-profits, and government, all united in a commitment to share expertise, prepare, and serve, is the right recipe to address the needs of the world.”

“Pfizer applauds the creation of the International Science Reserve (ISR). The Covid-19 pandemic and climate change have demonstrated the urgent need for crisis-preparedness in the scientific community. We believe that the principles of “science without borders,” “pre-wired circuitry,” and open cross-collaboration will allow scientists to come together, provide innovative solutions and move “at the speed of science,” says Aida Habtezion, Senior Vice President, Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer Inc. “Pfizer has been at the forefront of the pandemic response, aligning with ISR’s focus on preparing and mobilizing scientists to augment existing response organizations in times of crisis. We are proud to be among the founding partners of this important initiative.”

“The work of the International Science Reserve aligns with UL’s mission of working for a safer world,” says Senior Vice President and Chief Scientist at UL, Robert Slone. “We believe that anticipating and planning for high-risk events such as wildfires, pandemics and electrical grid failures are key to responsible corporate citizenship.”

The structure of the ISR is flexible and able to adapt to needs before, during, and after a complex global crisis. To explore and plan responses to possible crisis scenarios, a widespread network of 1000+ scientists is engaged in the ISR community. In addition to the scientists, executive board and funders, the ISR is building a global network of collaborators and members to augment and accelerate crisis response.

For the first readiness exercise, the ISR has engaged scientists to address the increasing devastating wildfires around the world. Recently, a first-ever United Nations scientific assessment on wildfire risks concluded that crippling wildfires could grow by nearly 60% by the end of this century – largely due to consequences of climate change. In the last two decades, there has been a sharp increase in wildfire season length, wildfire frequency and acreage burned.  

The network of scientists directly recruited by the ISR are well-equipped to rise to this challenge due to their deep expertise and knowledge around crisis resolution. As a first test of the operating model of the ISR, the ISR Readiness Exercises for its pilot crisis area, Wildfires, has begun, and the ISR team has been synthesizing findings which will be shared with the scientific community at a later date.

About the International Science Reserve

The International Science Reserve (ISR) is a network of open scientific communities, bringing together specialized resources from across the globe to prepare for and help mitigate complex and urgent global crises. We focus solely on preparing and mobilizing scientists to augment existing response organizations.  The New York Academy of Sciences is the coordinating hub of the ISR.

Then there’s this post which has been deleted from the IBM website, but is still accessible on

“How did a Health Firm get Security Fast for Global Covid-19 Vaccine Trials”IBM Blog

In this blog, you can learn how Signal Health got security fast for global COVID-19 vaccine trials. Furthermore, I will shortly present the IBM Security MaaS360 with Watson solution.

Signant Health was enlisted as the electronic clinical outcome assessment (eCOA) partner for a global pharmaceuticals Phase III COVID-19 vaccine trials, which involved 30,000+ patients in six countries who spoke 17 languages. Due to the pandemic’s urgency, Signant Health had only days to achieve patient consent, compliance, and engagement through all study-ready mobile devices to complete its mission.

Using IBM Security MaaS360 with Watson, Signant Health had a single platform for patients and study teams to use kiosk mode, which enabled strict controls and security while keeping devices user friendly regardless of location. Additionally, the MaaS360 team delivered request for enhancement (RFE) to continuously support the large-scale device deployments and technical, process and contract issues. IBM MaaS360 helped Signant Health securely deliver vaccine trial results to Pfizer in just five weeks, from patients located everywhere from Argentina to Turkey.

A quick search just now for “Pfizer IBM” also showed the following Pfizer-IBM Press Releases & News:

Browse: Pfizer | Rigged Agenda | What’s in the Vials? | Graphene | 5G | IBM

Posts tagged: Internet of Things


Penny... on Health
Penny... on Health

Truth-seeker, ever-questioning, ever-learning, ever-researching, ever delving further and deeper, ever trying to 'figure it out'. This site is a legacy of sorts, a place to collect thoughts, notes, book summaries, & random points of interests.

DISCLAIMER: The information on this website is not medical science or medical advice. I do not have any medical training aside from my own research and interest in this area. The information I publish is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition. I just report my own results, understanding & research.